Browse > Article

Water Soluble Cyclosporine Monomethoxy Poly(ethyleneglycol) Conjugates as Potential Prod rugs  

Cho, Hoon (Kuhnil Pharmaceutical Co. LTD.)
Chung, Yong-Seog (Department of Chemistry, Institute for Basic Science, Chungbuk National University)
Publication Information
Archives of Pharmacal Research / v.27, no.6, 2004 , pp. 662-669 More about this Journal
Abstract
The highly water-soluble monomethoxypoly(ethyleneglycol) (mPEG) prod rugs of cyciosporin A(CsA) were synthesized. These prod rugs were prepared by initially preparing intermediate in the form of carbonate at the 3'-positions of CsA with chloromethyl chloroformate, in the pres-ence of a base to provide a 3'-carbonated CsA intermediate. Reaction of the CsA intermediate with mPEG derivative in the presence of a base provides the desired water-soluble prod rugs. As a model, we chose molecular weight 5 kDa mPEG in the reaction with CsA to give water soluble prodrugs. To prove that the prod rug is decomposed in the body to produce CsA, the enzymatic hydrolysis test was conducted using human liver homogenate at $37^{\circ}C$. The prodrug was decomposed in human liver homogenate to produce the active material, CsA, and the hydrolysis half-life ($t_{1/2}$) of the prodrug, KI-306 was 2.2 minutes at $37^{\circ}C$. However, a demon-stration of non-enzymatic conversion in pH 7.4 phosphate buffer was provided by the fact that the half-life ($t_{1/2}$) is 21 hours at 37$^{\circ}C$. The hydrolysis test in rat whole blood was also conducted. The hydrolysis was seen with half-life ($t_{1/2}$) of about 9.9, 65.0, 14.2, 3.4, 2.1 9.5, and 1.6 minutes for KI-306, 309, 312, 313, 315, 316, and 317, respectively. This is the ideal for CsA prodrug. The pharmacokinetic study of the prodrug, KI-306, in comparison to the commer-cial product (Sandimmune Neoral Solution) was also carried out after single oral dose. Each rat received 7 mg/kg of CsA equivalent dose. Especially, the prodrug KI-306 exhibits higher AUC and $C_{max}$ than the conventional Neoral. The AUC and $C_{max}$ were increased nearly 1.5 fold. The kinetic value was also seen with $T_{max}$ of about 1.43 and 2.44 hours for KI-306 and Neoral, respectively.
Keywords
Cyciosporine; PEG; Prodrug; Polymer conjugate;
Citations & Related Records

Times Cited By Web Of Science : 2  (Related Records In Web of Science)
Times Cited By SCOPUS : 2
연도 인용수 순위
1 Drewe, J., Beglinger, C., and Kissel, T., The absorption site of cyclosporin in the human gastrointestinal tract. Br. J. Clin Pharmacol., 33(1), 39-43 (1992)   DOI   PUBMED   ScienceOn
2 Maeda, H., SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv.Drug Deliv. Rev,6, 181-202 (1991)   DOI   ScienceOn
3 Maeda, H., Seymour, L. W., and Miyamoto, Y., Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem., 3, 351-362 (1992)   DOI   PUBMED
4 Ymaoka, T., Tabata, Y, and Ikada, Y., Distribution and tissue uptake of polyethylene glycol with different molecular weights after intravenous administration to mice. J. Pham. Sci., 83, 601-606 (1994)   DOI   ScienceOn
5 McEvoy, G. K., ed. AHFS drug information. Bethesda, M. D., American Society of Health-System Pharmacists, 3057 (1998)
6 Noble, S. and Markham, A., Cyclosporine: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs, 50, 924 (1995)   DOI   ScienceOn
7 Shibata, N., Morita , K., Ono, T., Nishikawa, S., Kinoshita, M., Kawakita, S., Takada, K., Muranishi, S., and Shimakawa, H., Effects of diltiazem on rheological properties of human blood. Jourmal of pharmacobio-dynamics, 11(3), 175-180 (1988)   DOI   PUBMED
8 Fahr, A., Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet., 24(6), 472-495 (1993). Review   DOI   PUBMED   ScienceOn
9 Faulds, D., Goa, K. L., and Benfield, P, Cyclosporine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs, 45, 953 (1993)   DOI   ScienceOn
10 Strom ,T. B. and Tilney, N. L., Immunobiology and immunopharmacology of graft rejection. In: Schrier, R. W., Gottschalk, C. W., eds. Diseases of the Kidney [ed 5]. Boston, Little, Brown, 2879 (1993)
11 Abella, I., Pharmacoeconomics of Neoral, a new formulation of cyclosporine, in renal transplantation. Transplant Proc., 28, 3131 (1996)   PUBMED
12 Matthew, A. E., Mejillano, M. R., Nath, J. P., Himes, R. H., and Stella, V. J., Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J. Med. Chem., 35, 145-157 (1992)   DOI   PUBMED
13 Diasio, R. B. and LoBuglio. A. F., Immunomodulators: immunosuppressive agents and immunostimulants. In: Hardman, J. G., Goodman, L. S., Gillman, A., Limbird, L. E., eds. Goodman and Gillmans the pharmacological basis of therapeutics [ed.9]. New York, McGraw-Hill, 1291 (1996)
14 Noguchi, Y, Wun, J., Duncan , R., Strohalm, R., Ulbrich,K., Akaike, T., and Maeda, H., Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res., 89, 307-314 (1998)   DOI